Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Plus Therapeutics emphasizes the recent NCCN update for CNS cancers, reinforcing cerebrospinal fluid analysis including the use of its CNSide assay platform in diagnosing and monitoring leptomeningeal metastases (LM). CNSide shows improved sensitivity over conventional cytology and is expanding U.S. commercial coverage. The company plans a rebrand …